135248-89-4 Usage
Description
Fmoc-L-Cysteine, also known as N-(9-fluorenylmethoxycarbonyl)-L-cysteine, is an amino acid derivative that serves as a crucial building block in the synthesis of peptides and proteins. It is the N-Fmoc-protected form of L-Cysteine, a non-essential α-amino acid that is biosynthesized in humans. L-Cysteine is also a bicarbonate-sensitive endogenous excitotoxin in rats and possibly humans. Fmoc-L-Cysteine is characterized by its white crystalline powder appearance.
Uses
Used in Pharmaceutical Industry:
Fmoc-L-Cysteine is used as a building block for the synthesis of peptides and proteins, which are essential components in the development of various pharmaceutical products. Its role in the pharmaceutical industry is to facilitate the creation of complex peptide structures that can be used as therapeutic agents or for research purposes.
Used in Research and Development:
Fmoc-L-Cysteine is used as a research tool for studying the properties and functions of peptides and proteins. It is particularly useful in the field of biochemistry and molecular biology, where it can be employed to investigate the interactions between different biomolecules and their roles in cellular processes.
Used in Chemical Synthesis:
Fmoc-L-Cysteine is used as a reagent in the chemical synthesis of various compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its versatility as a building block allows for the creation of a wide range of products with diverse applications.
Used in Biochemical Assays:
Fmoc-L-Cysteine is used as a component in biochemical assays to study the activity of enzymes and other proteins that interact with cysteine-containing peptides. These assays can provide valuable information about the mechanisms of action and potential applications of these proteins in various biological processes.
Used in Drug Delivery Systems:
Fmoc-L-Cysteine can be used in the development of drug delivery systems, particularly for the targeted delivery of therapeutic peptides and proteins. Its ability to form stable peptide structures can be exploited to create carriers that can protect and transport drugs to specific sites within the body, improving their efficacy and reducing side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 135248-89-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,2,4 and 8 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 135248-89:
(8*1)+(7*3)+(6*5)+(5*2)+(4*4)+(3*8)+(2*8)+(1*9)=134
134 % 10 = 4
So 135248-89-4 is a valid CAS Registry Number.
135248-89-4Relevant articles and documents
Peptide Tethering: Pocket-Directed Fragment Screening for Peptidomimetic Inhibitor Discovery
Arora, Paramjit S.,Marrone, Frank,Modell, Ashley E.,Panigrahi, Nihar R.,Zhang, Yingkai
supporting information, p. 1198 - 1204 (2022/02/05)
Constrained peptides have proven to be a rich source of ligands for protein surfaces, but are often limited in their binding potency. Deployment of nonnatural side chains that access unoccupied crevices on the receptor surface offers a potential avenue to
Disulfide-Based Protecting Groups for the Cysteine Side Chain
Albericio, Fernando,Chakraborty, Amit,De La Torre, Beatriz G.,Sharma, Anamika
supporting information, p. 9644 - 9647 (2020/12/21)
Two new disulfide-based protecting groups (SIT and MOT) are proposed for Cys thiol in the substitution of StBu, which is often difficult to remove. Both groups are based on a secondary thiol with a branched point in the β-position for an efficient modulat
VERSATILE PEPTIDE AND PROTEIN MACROCYCLIZATION AND MULTIMERIZATION WITH DIELS-ALDER CYCLOADDITIONS
-
Paragraph 0141, (2020/10/21)
The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, compl
